The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.
United States President Donald Trump, Eli Lilly and Novo Nordisk have unveiled a deal to slash the prices of popular GLP-1 weight‑loss drugs for the government’s Medicare and Medicaid programme, as well as for cash payers.
The deal, announced on Thursday, is aimed at increasing access to treatments through US Medicare for people aged 65 and above and the Medicaid programme for low-income people, which together provide healthcare coverage for nearly half of all Americans.
US patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been p
Continue Reading on Al Jazeera
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.